Diana Danca’s practice focuses on intellectual property and patent infringement matters, emphasizing chemical, biotech, and pharmaceutical patent litigation, under the Hatch-Waxman Act and BPCIA. In addition, she conducts due diligence investigations related to mergers and acquisitions and has rendered opinions on patentability and patent infringement issues. Diana’s patent experience spans matters involving a wide range of technologies, including cancer, CNS, ophthalmic disease areas, drug delivery and formulations, small molecule, enantiomers, polymorphs, protein drug product, and protein chemistry and purification.
Before practicing law, Diana worked for several biotech companies as a medicinal chemist, designing and synthesizing novel compounds. She is the co-inventor of NINLARO®, a novel oral proteasome inhibitor approved in 2015 for the treatment of multiple myeloma, and a kinase inhibitor that was tested in Phase I clinical trials. Diana is also a co-inventor on several compound, formulation, and method of treatment pharmaceutical patents. Additionally, she is co-author of several scientific publications in the field of organic and medicinal chemistry.